{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T02:15:00Z","timestamp":1787537700369,"version":"build-2736575974"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>T-prolymphocytic leukemia (T-PLL) typically presents with rapidly progressing tumor burden. However, 15\u201325% of cases are diagnosed at an indolent stage with asymptomatic and stable low-level blood lymphocytosis over up to 2-3 years before advancing to active-stage disease. To define the molecular changes underlying this transition, we perform single-cell RNA sequencing of 28 treatment-na\u00efve samples including 11 longitudinally acquired indolent\/active pairs, paralleled by longitudinal whole genome sequencing. This reveals both patient-specific lesions and common global alterations of gene expression. Strong upregulations of MYC-target gene signatures in active T-PLL samples associated with enhanced energy metabolism implicate acquired autonomy from energetic restrictions. Recurrent downregulation of genes of the T-cell-receptor signaling cascade and reduced interactions of the T-PLL cell with non-leukemic cell types further indicate progressive independence from regulatory survival signals and escape from micromilieu-mediated control. This single-cell and disease-stage resolved genomic analysis of T-PLL provides insights into shared mechanisms of tumor evolution, which have to prove their amenability as targetable lesions.<\/jats:p>","DOI":"10.1038\/s41467-026-70185-w","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T09:34:27Z","timestamp":1773048867000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Single-cell genomics highlight MYC-associated metabolic activation and altered cell interactions in T-prolymphocytic leukemia progression"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4391-2601","authenticated-orcid":false,"given":"Linus","family":"Wahnschaffe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Jungherz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony A.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2951-4905","authenticated-orcid":false,"given":"Tea","family":"Pemovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9017-9343","authenticated-orcid":false,"given":"Alexander","family":"Pichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Poulain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3325-8107","authenticated-orcid":false,"given":"Edith","family":"Julia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8139-5950","authenticated-orcid":false,"given":"Sanna","family":"Timonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2911-8830","authenticated-orcid":false,"given":"Martin","family":"B\u00f6ttcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8517-7750","authenticated-orcid":false,"given":"Qu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Beverungen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Bischoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Franitza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4066-9257","authenticated-orcid":false,"given":"Theodoros","family":"Georgomanolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7897-7181","authenticated-orcid":false,"given":"Kerstin","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7425-4455","authenticated-orcid":false,"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2817-6660","authenticated-orcid":false,"given":"Dimitrios","family":"Mougiakakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7890-9845","authenticated-orcid":false,"given":"Thorsten","family":"Zenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0816-8241","authenticated-orcid":false,"given":"Satu","family":"Mustjoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2694-7510","authenticated-orcid":false,"given":"Emmanuel","family":"Bachy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4910-476X","authenticated-orcid":false,"given":"Charles","family":"Herbaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8774-3021","authenticated-orcid":false,"given":"Alexandra","family":"Schrader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natali","family":"Pflug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp B.","family":"Staber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0854-7815","authenticated-orcid":false,"given":"Till","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7473-7476","authenticated-orcid":false,"given":"Marco","family":"Herling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"70185_CR1","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio, R. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukema 36, 1720\u20131748 (2022).","journal-title":"Leukema"},{"key":"70185_CR2","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1182\/blood.2019000402","volume":"134","author":"PB Staber","year":"2019","unstructured":"Staber, P. B. et al. Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. Blood 134, 1132\u20131143 (2019).","journal-title":"Blood"},{"key":"70185_CR3","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/annonc\/mdx163","volume":"28","author":"P Jain","year":"2017","unstructured":"Jain, P. et al. Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL). Ann. Oncol. 28, 1554\u20131559 (2017).","journal-title":"Ann. Oncol."},{"key":"70185_CR4","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1182\/blood.V78.12.3269.3269","volume":"78","author":"E Matutes","year":"1991","unstructured":"Matutes, E. et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 78, 3269\u20133274 (1991).","journal-title":"Blood"},{"key":"70185_CR5","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1309\/93P42RNG5XBG3KBE","volume":"123","author":"JR Valbuena","year":"2005","unstructured":"Valbuena, J. R. et al. T-cell prolymphocytic leukemia involving extramedullary sites. Am. J. Clin. Pathol. 123, 456\u2013464 (2005).","journal-title":"Am. J. Clin. Pathol."},{"key":"70185_CR6","doi-asserted-by":"publisher","unstructured":"Hofmann, S. et al. Severely itching dermatitis and palmoplantar keratoderma as first manifestation of t-cell prolymphocytic leukaemia. Acta Dermato Venereol. https:\/\/doi.org\/10.2340\/00015555-3288 (2019).","DOI":"10.2340\/00015555-3288"},{"key":"70185_CR7","doi-asserted-by":"publisher","unstructured":"Braun, T., von Jan, J., Wahnschaffe, L. & Herling, M. Advances and Perspectives in the Treatment of T-PLL. Curr. Hematol. Malig. Rep. 1\u201312 https:\/\/doi.org\/10.1007\/s11899-020-00566-5 (2020).","DOI":"10.1007\/s11899-020-00566-5"},{"key":"70185_CR8","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1182\/blood-2012-01-380139","volume":"120","author":"C Dearden","year":"2012","unstructured":"Dearden, C. How I treat prolymphocytic leukemia. Blood 120, 538\u2013551 (2012).","journal-title":"Blood"},{"key":"70185_CR9","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1182\/blood.V98.6.1721","volume":"98","author":"CE Dearden","year":"2001","unstructured":"Dearden, C. E. et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 98, 1721\u20131726 (2001).","journal-title":"Blood"},{"key":"70185_CR10","doi-asserted-by":"publisher","first-page":"5799","DOI":"10.1182\/blood-2011-08-372854","volume":"118","author":"CE Dearden","year":"2011","unstructured":"Dearden, C. E. et al. Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route. Blood 118, 5799\u20135802 (2011).","journal-title":"Blood"},{"key":"70185_CR11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/ejh.12462","volume":"94","author":"M Herling","year":"2015","unstructured":"Herling, M. Are we improving the outcome for patients with T-cell prolymphocytic leukemia by allogeneic stem cell transplantation?. Eur. J. Haematol. 94, 191\u2013192 (2015).","journal-title":"Eur. J. Haematol."},{"key":"70185_CR12","doi-asserted-by":"publisher","first-page":"187.e1","DOI":"10.1016\/j.jtct.2022.01.017","volume":"28","author":"HS Murthy","year":"2022","unstructured":"Murthy, H. S. et al. Outcomes of allogeneic hematopoietic cell transplantation in T cell prolymphocytic leukemia: a contemporary analysis from the Center for International Blood and Marrow Transplant Research. Transplant. Cell. Ther. 28, 187.e1\u2013187.e10 (2022).","journal-title":"Transplant. Cell. Ther."},{"key":"70185_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02688-6","volume":"9","author":"A Schrader","year":"2018","unstructured":"Schrader, A. et al. Actionable perturbations of damage responses by TCL1\/ATM and epigenetic lesions form the basis of T-PLL. Nat. Commun. 9, 697 (2018).","journal-title":"Nat. Commun."},{"key":"70185_CR14","doi-asserted-by":"publisher","first-page":"4584","DOI":"10.3389\/fonc.2021.775363","volume":"11","author":"T Braun","year":"2021","unstructured":"Braun, T. et al. Advanced pathogenetic concepts in t-cell prolymphocytic leukemia and their translational impact. Front. Oncol. 11, 4584 (2021).","journal-title":"Front. Oncol."},{"key":"70185_CR15","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1182\/blood-2007-07-101519","volume":"111","author":"M Herling","year":"2008","unstructured":"Herling, M. et al. High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood 111, 328\u2013337 (2008).","journal-title":"Blood"},{"key":"70185_CR16","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/gcc.22821","volume":"59","author":"P Patil","year":"2020","unstructured":"Patil, P. et al. Reconstruction of rearranged T-cell receptor loci by whole genome and transcriptome sequencing gives insights into the initial steps of T-cell prolymphocytic leukemia. Genes Chromosomes Cancer 59, 261\u2013267 (2020).","journal-title":"Genes Chromosomes Cancer"},{"key":"70185_CR17","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3816\/CLM.2005.n.051","volume":"6","author":"F Ravandi","year":"2005","unstructured":"Ravandi, F. et al. T-cell prolymphocytic leukemia: a single-institution experience. Clin. Lymphoma Myeloma 6, 234\u2013239 (2005).","journal-title":"Clin. Lymphoma Myeloma"},{"key":"70185_CR18","doi-asserted-by":"publisher","first-page":"328 LP","DOI":"10.1182\/blood-2004-01-0002","volume":"104","author":"M Herling","year":"2004","unstructured":"Herling, M. et al. A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood 104, 328 LP\u2013328335 (2004).","journal-title":"Blood"},{"key":"70185_CR19","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1182\/blood.2019003348","volume":"136","author":"S Oberbeck","year":"2020","unstructured":"Oberbeck, S. et al. Noncanonical effector functions of the T-memory\u2013like T-PLL cell are shaped by cooperative TCL1A and TCR signaling. Blood 136, 2786\u20132802 (2020).","journal-title":"Blood"},{"key":"70185_CR20","doi-asserted-by":"publisher","first-page":"5638","DOI":"10.1038\/sj.onc.1204596","volume":"20","author":"Y Pekarsky","year":"2001","unstructured":"Pekarsky, Y., Hallas, C. & Croce, C. M. The role of TCL1 in human T-cell leukemia. Oncogene 20, 5638\u20135643 (2001).","journal-title":"Oncogene"},{"key":"70185_CR21","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1097-2765(00)00039-3","volume":"6","author":"J Laine","year":"2000","unstructured":"Laine, J., K\u00fcnstle, G., Obata, T., Sha, M. & Noguchi, M. The protooncogene TCL1 is an Akt kinase coactivator. Mol. Cell 6, 395\u2013407 (2000).","journal-title":"Mol. Cell"},{"key":"70185_CR22","doi-asserted-by":"publisher","first-page":"4406","DOI":"10.1182\/blood-2006-11-059501","volume":"110","author":"G Despouy","year":"2007","unstructured":"Despouy, G., Joiner, M., Le Toriellec, E., Weil, R. & Stern, M. H. The TCL1 oncoprotein inhibits activation-induced cell death by impairing PKC\u03b8 and ERK pathways. Blood 110, 4406\u20134416 (2007).","journal-title":"Blood"},{"key":"70185_CR23","doi-asserted-by":"publisher","first-page":"864","DOI":"10.4049\/jimmunol.175.2.864","volume":"175","author":"KK Hoyer","year":"2005","unstructured":"Hoyer, K. K. et al. T cell leukemia-1 modulates TCR signal strength and IFN-gamma levels through phosphatidylinositol 3-kinase and protein kinase C pathway activation. J. Immunol. 175, 864\u2013873 (2005).","journal-title":"J. Immunol."},{"key":"70185_CR24","doi-asserted-by":"crossref","unstructured":"Stachelscheid, J., Jiang, Q. & Herling, M. The modes of dysregulation of the proto-oncogene T-cell leukemia\/lymphoma 1A. Cancers (Basel) 13, 5455 (2021).","DOI":"10.3390\/cancers13215455"},{"key":"70185_CR25","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1182\/blood-2014-03-559542","volume":"124","author":"MJ Kiel","year":"2014","unstructured":"Kiel, M. J. et al. Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. Blood 124, 1460\u20131472 (2014).","journal-title":"Blood"},{"key":"70185_CR26","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/nm1097-1155","volume":"3","author":"S Stilgenbauer","year":"1997","unstructured":"Stilgenbauer, S. et al. Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. Nat. Med. 3, 1155\u20131159 (1997).","journal-title":"Nat. Med."},{"key":"70185_CR27","doi-asserted-by":"publisher","first-page":"626","DOI":"10.18632\/oncotarget.26595","volume":"10","author":"A Schrader","year":"2019","unstructured":"Schrader, A., Braun, T. & Herling, M. The dawn of a new era in treating T-PLL. Oncotarget 10, 626\u2013628 (2019).","journal-title":"Oncotarget"},{"key":"70185_CR28","first-page":"1694","volume":"9","author":"SH Maljaie","year":"1995","unstructured":"Maljaie, S. H. et al. Expression of c-myc oncoprotein in chronic T cell leukemias. Leukemia 9, 1694\u20131699 (1995).","journal-title":"Leukemia"},{"key":"70185_CR29","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/gcc.22313","volume":"55","author":"A Stengel","year":"2016","unstructured":"Stengel, A. et al. Genetic characterization of T-PLL reveals two major biologic subgroups and JAK3 mutations as prognostic marker. Genes Chromosomes Cancer 55, 82\u201394 (2016).","journal-title":"Genes Chromosomes Cancer"},{"key":"70185_CR30","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.3390\/cancers11121833","volume":"11","author":"L Wahnschaffe","year":"2019","unstructured":"Wahnschaffe, L. et al. JAK\/STAT-activating genomic alterations are a hallmark of T-PLL. Cancers (Basel) 11, 1833 (2019).","journal-title":"Cancers (Basel)"},{"key":"70185_CR31","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1046\/j.1365-2141.1998.00977.x","volume":"103","author":"R Garand","year":"1998","unstructured":"Garand, R. et al. Indolent course as a relatively frequent presentation in T- prolymphocytic leukaemia. Br. J. Haematol. 103, 488\u2013494 (1998).","journal-title":"Br. J. Haematol."},{"key":"70185_CR32","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/s12185-012-1077-y","volume":"95","author":"J Kameoka","year":"2012","unstructured":"Kameoka, J. et al. T-cell prolymphocytic leukemia in Japan: is it a variant?. Int. J. Hematol. 95, 660\u2013667 (2012).","journal-title":"Int. J. Hematol."},{"key":"70185_CR33","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1073\/pnas.95.7.3885","volume":"95","author":"L Virgilio","year":"1998","unstructured":"Virgilio, L. et al. Deregulated expression of TCL1 causes T cell leukemia in mice. Proc. Natl. Acad. Sci. USA 95, 3885\u20133889 (1998).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"70185_CR34","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587.e29 (2021).","journal-title":"Cell"},{"key":"70185_CR35","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3324\/haematol.2020.267500","volume":"107","author":"T Braun","year":"2022","unstructured":"Braun, T. et al. Micro-RNA networks in T-cell prolymphocytic leukemia reflect T-cell activation and shape DNA damage response and survival pathways. Haematologica 107, 187\u2013200 (2022).","journal-title":"Haematologica"},{"key":"70185_CR36","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417 (2015).","journal-title":"Cell Syst."},{"key":"70185_CR37","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 28, 1947\u20131951 (2019).","journal-title":"Protein Sci."},{"key":"70185_CR38","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/s43018-021-00216-6","volume":"2","author":"J Lu","year":"2021","unstructured":"Lu, J. et al. Multi-omics reveals clinically relevant proliferative drive associated with mTOR-MYC-OXPHOS activity in chronic lymphocytic leukemia. Nat. Cancer 2, 853 (2021).","journal-title":"Nat. Cancer"},{"key":"70185_CR39","first-page":"1","volume":"5","author":"Y Dong","year":"2020","unstructured":"Dong, Y., Tu, R., Liu, H. & Qing, G. Regulation of cancer cell metabolism: oncogenic MYC in the driver\u2019s seat. Signal Transduct. Target. Ther. 5, 1\u201311 (2020).","journal-title":"Signal Transduct. Target. Ther."},{"key":"70185_CR40","doi-asserted-by":"crossref","unstructured":"Morrish, F. & Hockenbery, D. MYC and Mitochondrial Biogenesis. Cold Spring Harb. Perspect. Med. 4, a014225 (2014).","DOI":"10.1101\/cshperspect.a014225"},{"key":"70185_CR41","volume":"42","author":"AC Andrew Cicchetto","year":"2023","unstructured":"Andrew Cicchetto, A. C. et al. ZFP36-mediated mRNA decay regulates metabolism. CellReports 42, 112411 (2023).","journal-title":"CellReports"},{"key":"70185_CR42","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1002\/2211-5463.13303","volume":"11","author":"A Ali","year":"2021","unstructured":"Ali, A. et al. Ferritin heavy chain (FTH1) exerts significant antigrowth effects in breast cancer cells by inhibiting the expression of c-MYC. FEBS Open Bio 11, 3101\u20133114 (2021).","journal-title":"FEBS Open Bio"},{"key":"70185_CR43","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1101\/gr.240663.118","volume":"29","author":"L Garcia-Alonso","year":"2019","unstructured":"Garcia-Alonso, L., Holland, C. H., Ibrahim, M. M., Turei, D. & Saez-Rodriguez, J. Benchmark and integration of resources for the estimation of human transcription factor activities. Genome Res. 29, 1363\u20131375 (2019).","journal-title":"Genome Res."},{"key":"70185_CR44","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nri2470","volume":"9","author":"M Perretti","year":"2009","unstructured":"Perretti, M. & D\u2019Acquisto, F. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat. Rev. Immunol. 9, 62\u201370 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"70185_CR45","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.3390\/cells10092245","volume":"10","author":"TG Ara\u00fajo","year":"2021","unstructured":"Ara\u00fajo, T. G. et al. Annexin A1 as a regulator of immune response in cancer. Cells 10, 2245 (2021).","journal-title":"Cells"},{"key":"70185_CR46","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1097\/PAS.0000000000000272","volume":"38","author":"AC Hsi","year":"2014","unstructured":"Hsi, A. C. et al. T-cell prolymphocytic leukemia frequently shows cutaneous involvement and is associated with gains of MYC, loss of ATM, and TCL1A rearrangement. Am. J. Surg. Pathol. 38, 1468\u20131483 (2014).","journal-title":"Am. J. Surg. Pathol."},{"key":"70185_CR47","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/86308","volume":"2","author":"NC Douglas","year":"2001","unstructured":"Douglas, N. C., Jacobs, H., Bothwell, A. L. M. & Hayday, A. C. Defining the specific physiological requirements for c-Myc in T cell development. Nat. Immunol. 2, 307\u2013315 (2001).","journal-title":"Nat. Immunol."},{"key":"70185_CR48","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.immuni.2011.09.021","volume":"35","author":"R Wang","year":"2011","unstructured":"Wang, R. et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity 35, 871 (2011).","journal-title":"Immunity"},{"key":"70185_CR49","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.53725","volume":"9","author":"JM Marchingo","year":"2020","unstructured":"Marchingo, J. M., Sinclair, L. V., Howden, A. J. & Cantrell, D. A. Quantitative analysis of how myc controls T cell proteomes and metabolic pathways during T cell activation. Elife 9, e53725 (2020).","journal-title":"Elife"},{"key":"70185_CR50","doi-asserted-by":"publisher","unstructured":"Whitfield, J. R. & Soucek, L. MYC in cancer: from undruggable target to clinical trials. Nat. Rev. Drug Discov. 2025 1\u201313 https:\/\/doi.org\/10.1038\/s41573-025-01143-2 (2025).","DOI":"10.1038\/s41573-025-01143-2"},{"key":"70185_CR51","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41591-024-02805-1","volume":"30","author":"E Garralda","year":"2024","unstructured":"Garralda, E. et al. MYC targeting by OMO-103 in solid tumors: a phase 1 trial. Nat. Med. 30, 762\u2013771 (2024).","journal-title":"Nat. Med."},{"key":"70185_CR52","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/leu.2017.252","volume":"32","author":"EI Andersson","year":"2018","unstructured":"Andersson, E. I. et al. Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling. Leukemia 32, 774\u2013787 (2018).","journal-title":"Leukemia"},{"key":"70185_CR53","doi-asserted-by":"publisher","first-page":"204062072093376","DOI":"10.1177\/2040620720933761","volume":"11","author":"P Johansson","year":"2020","unstructured":"Johansson, P. et al. Anti-leukemic effect of CDK9 inhibition in T-cell prolymphocytic leukemia. Ther. Adv. Hematol. 11, 204062072093376 (2020).","journal-title":"Ther. Adv. Hematol."},{"key":"70185_CR54","doi-asserted-by":"crossref","unstructured":"Llombart, V. & Mansour, M. R. Therapeutic targeting of \u2018undruggable\u2019 MYC. EBioMedicine 75, 103756 (2022).","DOI":"10.1016\/j.ebiom.2021.103756"},{"key":"70185_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-87890-9","volume":"11","author":"S Tian","year":"2021","unstructured":"Tian, S. et al. Epigenetic alteration contributes to the transcriptional reprogramming in T-cell prolymphocytic leukemia. Sci. Rep. 11, 1\u201314 (2021).","journal-title":"Sci. Rep."},{"key":"70185_CR56","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1158\/0008-5472.CAN-21-1908","volume":"82","author":"T Braun","year":"2022","unstructured":"Braun, T. et al. Noncanonical function of AGO2 augments t-cell receptor signaling in T-cell prolymphocytic leukemia. Cancer Res. 82, 1818\u20131831 (2022).","journal-title":"Cancer Res."},{"key":"70185_CR57","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1038\/leu.2012.142","volume":"26","author":"S Newrzela","year":"2012","unstructured":"Newrzela, S. et al. T-cell receptor diversity prevents T-cell lymphoma development. Leukemia 26, 2499\u20132507 (2012).","journal-title":"Leukemia"},{"key":"70185_CR58","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1309\/AJCPG71KYOXTKLQW","volume":"140","author":"X Chen","year":"2013","unstructured":"Chen, X. & Cherian, S. Immunophenotypic characterization of t-cell prolymphocytic leukemia. Am. J. Clin. Pathol. 140, 727\u2013735 (2013).","journal-title":"Am. J. Clin. Pathol."},{"key":"70185_CR59","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1182\/blood-2018-03-840611","volume":"132","author":"B Thakral","year":"2018","unstructured":"Thakral, B. & Wang, S. A. T-cell prolymphocytic leukemia negative for surface CD3 and CD45. Blood 132, 111\u2013111 (2018).","journal-title":"Blood"},{"key":"70185_CR60","doi-asserted-by":"crossref","unstructured":"Courtney, A. H. et al. CD45 functions as a signaling gatekeeper in T cells. Sci. Signal. 12, eaaw8151 (2019).","DOI":"10.1126\/scisignal.aaw8151"},{"key":"70185_CR61","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1136\/jclinpath-2020-206927","volume":"74","author":"MA Al Barashdi","year":"2021","unstructured":"Al Barashdi, M. A., Ali, A., McMullin, M. F. & Mills, K. Protein tyrosine phosphatase receptor type C (PTPRC or CD45). J. Clin. Pathol. 74, 548\u2013552 (2021).","journal-title":"J. Clin. Pathol."},{"key":"70185_CR62","doi-asserted-by":"crossref","unstructured":"Kwart, D. et al. Cancer cell-derived type I interferons instruct tumor monocyte polarization. Cell Rep. 41, 111769 (2022).","DOI":"10.1016\/j.celrep.2022.111769"},{"key":"70185_CR63","doi-asserted-by":"publisher","first-page":"5255","DOI":"10.2147\/IJGM.S431696","volume":"16","author":"M He","year":"2023","unstructured":"He, M., Yu, J., Chen, S. & Mi, H. A systematic immune and prognostic analysis of CD48 interaction with tumor microenvironment in pan-cancer. Int. J. Gen. Med. 16, 5255 (2023).","journal-title":"Int. J. Gen. Med."},{"key":"70185_CR64","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1182\/blood-2019-127453","volume":"134","author":"R Wu","year":"2019","unstructured":"Wu, R. et al. Epigenetic modulation of CD48 by NPM-ALK promotes immune evasion in ALK\u2009+\u2009ALCL. Blood 134, 1510\u20131510 (2019).","journal-title":"Blood"},{"key":"70185_CR65","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1182\/blood.2022015646","volume":"140","author":"M Chiba","year":"2022","unstructured":"Chiba, M. et al. Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas. Blood 140, 1951\u20131963 (2022).","journal-title":"Blood"},{"key":"70185_CR66","doi-asserted-by":"crossref","unstructured":"Macy, A. M., Herrmann, L. M., Adams, A. C. & Hastings, K. T. Major histocompatibility complex class II in the tumor microenvironment: functions of nonprofessional antigen-presenting cells. Curr. Opin. Immunol. 83, 102330 (2023).","DOI":"10.1016\/j.coi.2023.102330"},{"key":"70185_CR67","doi-asserted-by":"publisher","first-page":"5054","DOI":"10.1182\/blood-2007-12-130609","volume":"111","author":"YC Chang","year":"2008","unstructured":"Chang, Y. C. et al. Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3. Blood 111, 5054\u20135063 (2008).","journal-title":"Blood"},{"key":"70185_CR68","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3, 991\u2013998 (2002).","journal-title":"Nat. Immunol."},{"key":"70185_CR69","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.3324\/haematol.2017.184192","volume":"103","author":"M de Charette","year":"2018","unstructured":"de Charette, M. & Houot, R. Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy. Haematologica 103, 1256 (2018).","journal-title":"Haematologica"},{"key":"70185_CR70","doi-asserted-by":"crossref","unstructured":"Pastorczak, A., Domka, K., Fidyt, K., Poprzeczko, M. & Firczuk, M. Mechanisms of immune evasion in acute lymphoblastic leukemia. Cancers (Basel). 13, 1536 (2021).","DOI":"10.3390\/cancers13071536"},{"key":"70185_CR71","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1182\/bloodadvances.2018030577","volume":"3","author":"LDS Johnson","year":"2019","unstructured":"Johnson, L. D. S. et al. Targeting CD47 in S\u00e9zary syndrome with SIRPaFc. Blood Adv. 3, 1145\u20131153 (2019).","journal-title":"Blood Adv."},{"key":"70185_CR72","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/S1470-2045(19)30320-1","volume":"20","author":"M Bagot","year":"2019","unstructured":"Bagot, M. et al. IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. Lancet Oncol. 20, 1160\u20131170 (2019).","journal-title":"Lancet Oncol."},{"key":"70185_CR73","doi-asserted-by":"crossref","unstructured":"Vu, L. T. et al. Single-cell transcriptomics of the immune system in ME\/CFS at baseline and following symptom provocation. Cell Rep. Med. 5, 101373 (2024).","DOI":"10.1016\/j.xcrm.2023.101373"},{"key":"70185_CR74","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41586-019-1127-1","volume":"569","author":"S Nowotschin","year":"2019","unstructured":"Nowotschin, S. et al. The emergent landscape of the mouse gut endoderm at single-cell resolution. Nature 569, 361\u2013367 (2019).","journal-title":"Nature"},{"key":"70185_CR75","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888\u20131902.e21 (2019).","journal-title":"Cell"},{"key":"70185_CR76","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1093\/bioinformatics\/btx364","volume":"33","author":"JR Conway","year":"2017","unstructured":"Conway, J. R., Lex, A. & Gehlenborg, N. UpSetR: an R package for the visualization of intersecting sets and their properties. Bioinformatics 33, 2938\u20132940 (2017).","journal-title":"Bioinformatics"},{"key":"70185_CR77","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/bioinformatics\/btaa755","volume":"37","author":"M Andreatta","year":"2021","unstructured":"Andreatta, M. & Carmona, S. J. STACAS: sub-type anchor correction for alignment in Seurat to integrate single-cell RNA-seq data. Bioinformatics 37, 882\u2013884 (2021).","journal-title":"Bioinformatics"},{"key":"70185_CR78","first-page":"1438","volume":"5","author":"Y Chen","year":"2016","unstructured":"Chen, Y. et al. From reads to genes to pathways: differential expression analysis of RNA-Seq experiments using Rsubread and the edgeR quasi-likelihood pipeline. F1000Research 5, 1438 (2016).","journal-title":"F1000Research"},{"key":"70185_CR79","first-page":"1","volume":"12","author":"JW Squair","year":"2021","unstructured":"Squair, J. W. et al. Confronting false discoveries in single-cell differential expression. Nat. Commun. 2021 12:1 12, 1\u201315 (2021).","journal-title":"Nat. Commun. 2021 12:1"},{"key":"70185_CR80","doi-asserted-by":"publisher","unstructured":"Cannoodt, R. et al. SCORPIUS improves trajectory inference and identifies novel modules in dendritic cell development. bioRxiv 079509 https:\/\/doi.org\/10.1101\/079509 (2016).","DOI":"10.1101\/079509"},{"key":"70185_CR81","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"70185_CR82","first-page":"D498","volume":"48","author":"B Jassal","year":"2020","unstructured":"Jassal, B. et al. The reactome pathway knowledgebase. Nucleic Acids Res 48, D498\u2013D503 (2020).","journal-title":"Nucleic Acids Res"},{"key":"70185_CR83","doi-asserted-by":"crossref","unstructured":"Karolchik, D. et al. The UCSC Table Browser data retrieval tool. Nucleic Acids Res. 32, D493-6 (2004).","DOI":"10.1093\/nar\/gkh103"},{"key":"70185_CR84","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nature23306","volume":"548","author":"DR Robinson","year":"2017","unstructured":"Robinson, D. R. et al. Integrative clinical genomics of metastatic cancer. Nature 548, 297\u2013303 (2017).","journal-title":"Nature"},{"key":"70185_CR85","doi-asserted-by":"publisher","first-page":"4168","DOI":"10.1016\/j.cell.2021.05.045","volume":"184","author":"A Wagner","year":"2021","unstructured":"Wagner, A. et al. Metabolic modeling of single Th17 cells reveals regulators of autoimmunity. Cell 184, 4168\u20134185.e21 (2021).","journal-title":"Cell"},{"key":"70185_CR86","doi-asserted-by":"publisher","first-page":"D745","DOI":"10.1093\/nar\/gky1113","volume":"47","author":"F Cunningham","year":"2019","unstructured":"Cunningham, F. et al. Ensembl 2019. Nucleic Acids Res. 47, D745\u2013D751 (2019).","journal-title":"Nucleic Acids Res."},{"key":"70185_CR87","doi-asserted-by":"crossref","unstructured":"Badia-i-Mompel, P. et al. decoupleR: ensemble of computational methods to infer biological activities from omics data. Bioinform. Adv. 2, vbac016 (2022).","DOI":"10.7490\/f1000research.1119067.1"},{"key":"70185_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-21246-9","volume":"12","author":"S Jin","year":"2021","unstructured":"Jin, S. et al. Inference and analysis of cell-cell communication using CellChat. Nat. Commun. 12, 1\u201320 (2021).","journal-title":"Nat. Commun."},{"key":"70185_CR89","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41592-019-0667-5","volume":"17","author":"R Browaeys","year":"2020","unstructured":"Browaeys, R., Saelens, W. & Saeys, Y. NicheNet: modeling intercellular communication by linking ligands to target genes. Nat. Methods 17, 159\u2013162 (2020).","journal-title":"Nat. Methods"},{"key":"70185_CR90","unstructured":"Van der Auwera, G., O\u2019Connor, B. & Safari. Genomics in the Cloud: Using Docker, GATK, and WDL in Terra. O\u2019Reilly Media 300 (2020)."},{"key":"70185_CR91","doi-asserted-by":"publisher","first-page":"D891","DOI":"10.1093\/nar\/gkad1049","volume":"52","author":"PW Harrison","year":"2024","unstructured":"Harrison, P. W. et al. Ensembl 2024. Nucleic Acids Res. 52, D891\u2013D899 (2024).","journal-title":"Nucleic Acids Res."},{"key":"70185_CR92","doi-asserted-by":"crossref","unstructured":"Minoche, A. E. et al. ClinSV: clinical grade structural and copy number variant detection from whole genome sequencing data. Genome Med. 13, 32 (2021).","DOI":"10.1186\/s13073-021-00841-x"},{"key":"70185_CR93","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/sj.leu.2404017","volume":"20","author":"M Herling","year":"2006","unstructured":"Herling, M. et al. TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state. Leukemia 20, 280\u2013285 (2006).","journal-title":"Leukemia"},{"key":"70185_CR94","doi-asserted-by":"publisher","first-page":"1445454","DOI":"10.1080\/2162402X.2018.1445454","volume":"7","author":"M B\u00f6ttcher","year":"2018","unstructured":"B\u00f6ttcher, M. et al. D-2-hydroxyglutarate interferes with HIF-1\u03b1 stability skewing T-cell metabolism towards oxidative phosphorylation and impairing Th17 polarization. Oncoimmunology 7, 1445454 (2018).","journal-title":"Oncoimmunology"},{"key":"70185_CR95","doi-asserted-by":"crossref","unstructured":"Wickham, H. Ggplot2: Elegant Graphics for Data Analysis (Springer-Verlag New York, 2016).","DOI":"10.1007\/978-3-319-24277-4_9"},{"key":"70185_CR96","doi-asserted-by":"publisher","unstructured":"Wahnschaffe, L. et al. Single-cell genomics highlight MYC-associated metabolic ac-tivation and altered cell interactions in T-prolymphocytic leu-kemia progression. GitHub https:\/\/doi.org\/10.5281\/zenodo.17568926 (2025).","DOI":"10.5281\/zenodo.17568926"},{"key":"70185_CR97","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1182\/blood.2022015494","volume":"141","author":"J Stachelscheid","year":"2023","unstructured":"Stachelscheid, J. et al. The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL. Blood 141, 1425\u20131441 (2023).","journal-title":"Blood"},{"key":"70185_CR98","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood-2023-182877","volume":"142","author":"Q Jiang","year":"2023","unstructured":"Jiang, Q. et al. Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia. Blood 142, 44\u201361 (2023).","journal-title":"Blood"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70185-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70185-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70185-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T03:02:21Z","timestamp":1773198141000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70185-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":98,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["70185"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-70185-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"15 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.P. reports being a founder and shareholder of exalt\u00aeFlexCo, unrelated to the work. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2319"}}